Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- Registration Number
- NCT06787612
- Lead Sponsor
- Regeneron Pharmaceuticals
- Brief Summary
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer.
The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug and its experimental combinations
* How much study drug and fianlimab is in the blood at different times
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- Female
- Target Recruitment
- 220
- Participants with histologically or cytologically confirmed diagnosis of advanced serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer (clear cell, mucinous, and carcinosarcoma are excluded)
- Must have progression on prior therapy documented radiographically and must have at least 1 measurable lesion (not previously irradiated) that can be accurately measured by RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ and bone marrow function, as described in the protocol
- Platinum-Resistant Ovarian Cancer, as described in the protocol
Key
- Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study drug(s)
- Documented allergic or acute hypersensitivity reaction attributed to antibody treatments or doxorubicin hydrochloride or components of study drug(s)
- Another malignancy that is progressing or requires active treatment, as described in the protocol
- Untreated or active primary brain tumor, Central Nervous System (CNS) metastases, or spinal cord compression, as described in the protocol
- Uncontrolled infections including but not limited to human immunodeficiency virus, hepatitis B or hepatitis C infection, or diagnosis of immunodeficiency
NOTE: Other protocol-defined inclusion/exclusion criteria apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm A1 Ubamatamab Randomization as described in the protocol Arm A1 Sarilumab Randomization as described in the protocol Arm A2 Sarilumab Randomization as described in the protocol Arm B Bevacizumab Randomization as described in the protocol Arm B Sarilumab Randomization as described in the protocol Arm C Cemiplimab Randomization as described in the protocol Arm C Sarilumab Randomization as described in the protocol Arm D PLD Randomization as described in the protocol Arm D Sarilumab Randomization as described in the protocol Arm C Fianlimab Randomization as described in the protocol Arm A2 Ubamatamab Randomization as described in the protocol Arm B Ubamatamab Randomization as described in the protocol Arm C Ubamatamab Randomization as described in the protocol Arm D Ubamatamab Randomization as described in the protocol
- Primary Outcome Measures
Name Time Method Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessment Up to 3 years
- Secondary Outcome Measures
Name Time Method Cancer Antigen (CA) -125 response by Gynecologic Cancer Intergroup (GCIG) Criteria Up to 3 years Complete Response (CR) rate by RECIST 1.1 Up to 3 years Disease Control Rate (DCR) by RECIST 1.1 Up to 3 years Duration Of Response (DOR) by RECIST 1.1 Up to 3 years Progression-Free Survival (PFS) by RECIST 1.1 Up to 3 years Incidence of Grade ≥ 2 Cytokine Release Syndrome (CRS) by Lee criteria Up to 3 years Treatment-Emergent Adverse Events (TEAEs) by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Up to 3 years TEAEs by Lee criteria Up to 3 years Concentration of ubamatamab in serum over time Up to 3 years Concentration of fianlimab in serum over time Up to 3 years Incidence of anti-drug antibodies (ADA) to ubamatamab Up to 3 years Titer of ADA to ubamatamab Up to 3 years Incidence of ADA to fianlimab Up to 3 years Titer of ADA to fianlimab Up to 3 years Incidence of ADA to cemiplimab Up to 3 years Titer of ADA to cemiplimab Up to 3 years
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.